Patents by Inventor Dan Kiel

Dan Kiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION
    Publication number: 20110014225
    Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.
    Type: Application
    Filed: March 20, 2009
    Publication date: January 20, 2011
    Applicant: NOVARTIS AG
    Inventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Kiel
  • Non-peptide GLP-1 agonists
    Patent number: 6927214
    Abstract: Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 9, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Min Teng, Larry Kenneth Truesdale, Dilip Bhumralkar, Dan Kiel, Michael D. Johnson, Christine Thomas, Anker Steen Jorgensen, Peter Madsen, Preben Houlberg Olesen, Liselotte Bjerre Knudsen, Ingrid Vivika Petterson, Johannes Cornelis de Jong, Carsten Behrens, Janos Tibor Kodra, Jesper Lau
  • Glucagon antagonists/inverse agonists
    Patent number: 6613942
    Abstract: Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: September 2, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Ling, Vlad Gregor, Javier Gonzalez, Yufeng Hong, Dan Kiel, Atsuo Kuki, Shenghua Shi, Lars Naerum, Peter Madsen, Christian Sams, Jesper Lau, Michael Bruno Plewe, Jun Feng, Min Teng, Michael David Johnson, Kimberly Ann Teston, Ulla Grove Sidelmann, Lotte Bjerre Knudsen
  • Non-peptide antagonists of GLP-1 receptor and methods of use
    Patent number: 6469021
    Abstract: Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: October 22, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Larry Kenneth Truesdale, Richard A. Bychowski, Javier Gonzalez, Atsuo Kuki, Ranjan Jagath Rajapakse, Min Teng, Dan Kiel, Daljit S. Dhanoa, Yufeng Hong, Tso-sheng Chou, Anthony L. Ling, Michael David Johnson, Vlad Edward Gregor